Analysts Conflictied on These Healthcare Names: BioCryst (NASDAQ: BCRX), Aduro BioTech (NASDAQ: ADRO) and Chimerix (NASDAQ: CMRX)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioCryst (NASDAQ: BCRX), Aduro BioTech (NASDAQ: ADRO) and Chimerix (NASDAQ: CMRX).

BioCryst (NASDAQ: BCRX)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BioCryst (NASDAQ: BCRX) today. The company’s shares opened today at $4.67.

According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.5% and a 40.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies S.A. – American, and Proteostasis Therapeutics Inc.

BioCryst has an analyst consensus of Strong Buy.

Aduro BioTech (NASDAQ: ADRO)

FBR Capital analyst Christopher James reiterated a Buy rating on Aduro BioTech (NASDAQ: ADRO) yesterday. The company’s shares opened today at $12.55.

According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -22.7% and a 23.9% success rate. James covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Aviragen Therapeutics, Inc., and Achillion Pharmaceuticals.

Currently, the analyst consensus on Aduro BioTech is Strong Buy and the average price target is $14, representing an 11.6% upside.

In a report issued on October 24, Canaccord Genuity also reiterated a Buy rating on the stock with a $30 price target.
Chimerix (NASDAQ: CMRX)

FBR Capital analyst Edward White reiterated a Hold rating on Chimerix (NASDAQ: CMRX) yesterday and set a price target of $8. The company’s shares opened today at $4.10, close to its 52-week low of $3.50.

White commented:

“In conjunction with its earnings release November 7, Chimerix updated the Street on the progress that it has made with its pipeline with several milestones slated for 2017. The company is advancing the intravenous (IV) formulation of brincidofovir to address CMV, BK virus, and other DNA viral infections. Additionally, the company updated progress on CMX521, which is in preclinical studies for norovirus. We expect an IND to be filed in the back half of next year.”

According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -12.8% and a 19.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, RXi Pharmaceuticals Corp, and Synthetic Biologics Inc.

Chimerix has an analyst consensus of Moderate Buy.